Analytical Cellular Pathology, the predecessor of Cellular Oncology, to a steady level of around 4 over the last years, with a strong position in both the categories pathology and oncology. Against this background, the journal and ISCO have continued to look for opportunities that match our ambitions.
With the onset of 2011 we have entered into the second decade of this century. Many of us expect to witness this decade the full maturation of omics being turned into diagnostic and therapeutic applications that will improve clinical outcome in many diseases including oncology. So, many great things are about to happen.
In parallel to this, dear reader, you now witness a major step in the maturation of this journal. From 2011 onward, Cellular Oncology will be published by Springer. The editorial team as well as ISCO are very excited about this development, which will extend the possibilities to achieve our goals. Springer is one of the worlds leading scientific publishing companies. For Cellular Oncology to be part of their portfolio will provide many advantages. The journal will benefit from the larger market share that will make it more widely accessible, especially in areas that have been underserved in the past, like the US. At the same time, Cellular Oncology will come with state of the art services including SpringerLink and Springer Open Choice, as well as excellent facilities for hosting supplementary data, taking the professional status of the journal to the next level. This way more scientists will have access to the high level scientific content in Cellular Oncology, the authors who choose to publish their work in the journal will find themselves to reach a bigger audience, and we expect the journal to show a further increase in performance, and consequently impact factor and perhaps volume. The new spring heralds a bright future for Cellular Oncology.
